Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2023) 142 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2023-184431

Published: 2023

Journal Articles

Differences in Clinical Outcomes between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients

Sung-Yong Kim, Sung-Eun Lee, Junshik Hong, Soo-Mee Bang, Jinny Park, Chul Won Choi, Sung Hwa Bae, Min Kyoung Kim, Seug Yun Yoon

Blood (2023) 142 (Supplement 1): 1818.

https://doi.org/10.1182/blood-2023-177822

Published: 2023

Journal Articles

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park

Blood (2022) 140 (Supplement 1): 6850–6851.

https://doi.org/10.1182/blood-2022-168687

Published: 2022

Journal Articles

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Ka-Won Kang, Hyemi Moon, Byung-Hyun Lee, MD, Min Ji Jeon, Eun Sang Yu, MD, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, MD PhD, Chul Won Choi, Byung Soo Kim, Juneyoung Lee, Yong Park

Blood (2019) 134 (Supplement_1): 2227.

https://doi.org/10.1182/blood-2019-125269

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea

Yong Park, MD, Dae Sik Kim, MD PhD, Ka-Won Kang, MD, Byung-Hyun Lee, MD, Eun Sang Yu, MD, Min Ji Jeon, MD, Hojoon Choi, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Kihyun Kim, MD PhD, Byung Soo Kim, MD PhD, Seok Jin Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3347.

https://doi.org/10.1182/blood-2018-99-115625

Published: 2018

Journal Articles

Survival Benefit with Standard-Dose Decitabine Versus Standard-Dose Azacitidine in Patients with Lower-Risk Myelodysplastic Syndromes

Byung-Hyun Lee, MD, Ka-Won Kang, MD, Min Ji Jeon, MD, Eun Sang Yu, MD, Dae Sik Kim, MD PhD, Hojoon Choi, MD, Se Ryun Lee, MD PhD, Hwa Jung Sung, MD PhD, Yong Park, MD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2018-99-115694

Published: 2018

Journal Articles

Immature Platelet Fraction Based Diagnostic Predictive Model for Immune Thrombocytopenic Purpura

Min Ji Jeon, MD, Hojoon Choi, MD, Eun Sang Yu, MD, Ka-Won Kang, MD, Byung-Hyun Lee, MD, Dae Sik Kim, MD PhD, Yong Park, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2018) 132 (Supplement 1): 1149.

https://doi.org/10.1182/blood-2018-99-117754

Published: 2018

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

The Potential of Exosomes Derived from Chronic Myelogenous Leukemia Cells As Biomarker Based on the BCR-ABL mRNA Transcript

Ka-Won Kang, MD, Jik-han Jung, Woojune Hur, Jaena Park, Hyunku Shin, ByeongHyeon Choi, Hyesun Jeong, Dae Sik Kim, MD PhD, Eun Sang Yu, MD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Seok Jin Kim, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD, Hyun Koo Kim, MD PhD, Sunghoi Hong, PhD, Ji-ho Park, PhD, Yeonho Choi, PhD, Yong Park, MD PhD

Blood (2017) 130 (Supplement 1): 2883.

https://doi.org/10.1182/blood.V130.Suppl_1.2883.2883

Published: 2017

Journal Articles

the Safety and Efficacy of Pomalidomide in Combination with Cyclophosphamide and Dexamethasone (PCD) in the Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-Labeled, Multicenter Phase II Study

Ho Sup Lee, MD, Chang-Ki Min, MD PhD, Kihyun Kim, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, Dok Hyun Yoon, MD PhD, Cheolwon Suh, MD PhD, Ho-Jin Shin, MD, Yeung-Chul Mun, MD PhD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, MD PhD, Hye Jin Kang, MD PhD, Sung-Soo Yoon, MD PhD

Blood (2017) 130 (Supplement 1): 1834.

https://doi.org/10.1182/blood.V130.Suppl_1.1834.1834

Published: 2017

Journal Articles

Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party

Blood (2017) 130 (Supplement 1): 4257.

https://doi.org/10.1182/blood.V130.Suppl_1.4257.4257

Published: 2017

Journal Articles

Routine Imaging for Surveillance in Patients with Aggressive Non-Hodgkin Lymphoma in Complete Remission after Frontline Chemotherapy

Ka-Won Kang, MD, Dae Sik Kim, MD PhD, Eun Sang You, MD, Yong Park, MD PhD, Se Ryeon Lee, Hwa Jung Sung, MD PhD, Seok Jin Kim, Chul Won Choi, MD PhD, Byung Soo Kim

Blood (2016) 128 (22): 3041.

https://doi.org/10.1182/blood.V128.22.3041.3041

Published: 2016

Journal Articles

The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)

Sung-Hoon Jung, Je-Jung Lee, Kihyun Kim, MD PhD, Dok Hyun Yoon, Chang-Ki Min, Sang Kyun Sohn, MD, PhD, Chul Won Choi, Ho Sup Lee, Hyo Jung Kim, Ho-Jin Shin, MD PhD, Soo-Mee Bang, Sung-Soo Yoon, MD PhD, Seong Kyu Park, Ho-Young Yhim, Min Kyoung Kim, MD, Jae-Cheol Jo, MD PhD, Yeung-Chul Mun, Jae-Hoon Lee, Jin Seok Kim, MD PhD

Blood (2016) 128 (22): 4445.

https://doi.org/10.1182/blood.V128.22.4445.4445

Published: 2016

Journal Articles

Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies

Ka-Won Kang, MD, Yong Park, MD PhD, Dae Sik Kim, MD PhD, Se Ryeon Lee, MD PhD, Hwa Jung Sung, MD PhD, Seok Jin Kim, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2015) 126 (23): 4889.

https://doi.org/10.1182/blood.V126.23.4889.4889

Published: 2015

Journal Articles

High-Dose Cytarabine Alone Versus Cytarabine Plus Anthracycline for Consolidation Therapy in Non-Promyelocytic Acute Myeloid Leukemia

Sung-Hyun Kim, So Yeon Kim, Ji Hyun Lee, MD PhD, Suee Lee, Sung Yong Oh, Hyo-Jin Kim, Dae Sik Kim, MD, Ka-Won Kang, MD, Se Ryeon Lee, MD PhD, Yong Park, MD PhD, Hwa Jung Sung, MD PhD, Chul Won Choi, MD PhD, Byung Soo Kim, MD PhD

Blood (2015) 126 (23): 4890.

https://doi.org/10.1182/blood.V126.23.4890.4890

Published: 2015

Journal Articles

Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry

Jun Ho Jang, Jin Seok Kim, MD PhD, Deog-Yeon Jo, MD PhD, Je-Hwan Lee, MD PhD, Chul Won Choi, MD PhD, Hyeoung Joon Kim, MD PhD, Jong-Ho Won, MD PhD, Joo Seop Chung, MD PhD, Hawk Kim, MD PhD, Jae-Hoon Lee, MD PhD, Sang Kyun Sohn, MD PhD, Jeong A Kim, MD PhD, Jong Wook Lee, MD PhD

Blood (2015) 126 (23): 4789.

https://doi.org/10.1182/blood.V126.23.4789.4789

Published: 2015

Journal Articles

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Blood (2015) 126 (23): 476.

https://doi.org/10.1182/blood.V126.23.476.476

Published: 2015

Journal Articles

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Blood (2015) 126 (23): 4053.

https://doi.org/10.1182/blood.V126.23.4053.4053

Published: 2015

NARROW

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Differences in Clinical Outcomes between Hydroxyurea-Resistant and -Intolerant Polycythemia Vera Patients

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

One-Day Low-Dose Etoposide Is an Effective Chemomobilization Regimen with Minimal Toxicity for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Multicenter Study from Tertiary Hospitals in Korea

Survival Benefit with Standard-Dose Decitabine Versus Standard-Dose Azacitidine in Patients with Lower-Risk Myelodysplastic Syndromes

Immature Platelet Fraction Based Diagnostic Predictive Model for Immune Thrombocytopenic Purpura

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

The Potential of Exosomes Derived from Chronic Myelogenous Leukemia Cells As Biomarker Based on the BCR-ABL mRNA Transcript

Prognostic Factors and Response to the Hypomethylating Agents in Hypocellular Myelodysplastic Syndromes: A Retrospective Study from the Korean Society of Hematology AML/MDS Working Party

Routine Imaging for Surveillance in Patients with Aggressive Non-Hodgkin Lymphoma in Complete Remission after Frontline Chemotherapy

The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160)

Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7+3 regimen) Chemotherapies

High-Dose Cytarabine Alone Versus Cytarabine Plus Anthracycline for Consolidation Therapy in Non-Promyelocytic Acute Myeloid Leukemia

Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only